Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P21/00—Preparation of peptides or proteins
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
  • A01K67/027—New or modified breeds of vertebrates
  • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
  • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/46—Hybrid immunoglobulins
  • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2207/00—Modified animals
  • A01K2207/15—Humanized animals
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2217/00—Genetically modified animals
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2217/00—Genetically modified animals
  • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2227/00—Animals characterised by species
  • A01K2227/10—Mammal
  • A01K2227/105—Murine
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2267/00—Animals characterised by purpose
  • A01K2267/01—Animal expressing industrially exogenous proteins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide

Definitions

• This invention concerns the production of antibodies (or immunoglobulins) .
• a method of producing an immunoglobulin comprising obtaining immunoglobulin from cells or body fluid of a transgenic animal which has had inserted into its germline genetic material that encodes for at least part of an immunoglobulin of foreign origin or that can rearrange to encode a repertoire of immunoglobulins.
• An immunoglobulin of foreign origin means an immunoglobulin derived from a different animal source.
• the transgenic animal is a mouse
• the inserted genetic material is of non-mouse, e.g. human, origin.
• the inserted genetic material may be produced from an animal source, or may be produced synthetically.
• the material may code for at least part of a known immunoglobulin or may be modified to code for at least part of an altered immunoglobulin. Suitable techniques for these processes are well known.
• the inserted genetic material may be expressed in the transgenic animal, resulting in production of an immunoglobulin derived at least in part from the inserted material. It is found the genetic material is rearranged in the transgenic animal, so that a repertoire of immunoglobulinswith part or parts derived from inserted genetic material may be produced even if the inserted genetic material is incorporated in the germline in the wrong position or with the wrong geometry.
• the animal may produce a chimaeric immunoglobulin/ e.g. of mixed mouse/human origin, where the genetic material of foreign origin encodes only part of the immunoglobulin, or the animal may produce an entirely foreign immunoglobulin, e.g. of wholly human origin, where the genetic material of foreign origin encodes an entire immunoglobulin.
• Potentially therapeutically useful immunoglobulins suitable for use with humans thus may be produced by use of the invention.
• Polyclonal antisera may be produced from the transgenic animal following immunisation.
• monoclonal antibodies may be produced from the transgenic animal, eg by fusing spleen cells from the animal with myeloma cells and screening the resulting hybridomas to select those producing the desired antibody. Suitable techniques for such processes are well known to those skilled in the art.
• the genetic material may be incorporated in the animal in such a way that the desired antibody is produced in body fluids such as serum or external secretions of the animal, such as milk, colostrum or saliva.
• body fluids such as serum or external secretions of the animal, such as milk, colostrum or saliva.
• the desired antibody may then be harvested from the milk. Suitable techniques for carrying out such processes are known to those skilled in the art.
• Another possibility involves removal from the animal of immunoglobulin-producing cells generated by the animal after insertion of genetic material, followed by in vitro selection of cells producing an immunoglobulin of interest.
• the immunoglobulin can then be produced in vitro from the selected cells in known manner.
• transgenic animal can produce chimaeric or foreign immunoglobulin (derived from inserted genetic material) in response to an immunogen subsequently introduced to the animal. Accordingly, by introducing foreign, eg human, genetic material encoding for substantially the entire species specific regions of an immunoglobulin it may be possible to stimulate the animal to produce foreign immunoglobulin to any antigen introduced to the animal.
• the transgenic animal could thus provide a highly useful, convenient and valuable source of human immunoglobulins to a large range of antigens.
• the inserted genetic material may thus be in the form of DNA cloned into prokaryotic vectors such as ' plasmids and cosmids. Multiple plasmids or cosmids may also be used, but it is probably necessary for these to integrate in proximity on the genome.
• the inserted genetic material may be introduced to the host in conventional manner, for example by injection or other procedures into fertilised eggs or embryonic stem cells.
• the transgenic animal will carry the naturally occuring genetic material and the inserted genetic material and will produce immunoglobulins derived from the naturally occuring genetic material, the inserted genetic material and mixtures of both types of genetic material.
• the desired immunoglobulin can be obtained by screening hybridomas derived from the transgenic animal, eg by exploiting the phenomenon of allelic exclusion of antibody gene expression or differential chromosome loss.
• the present invention produces a transgenic animal, particularly a non-human mammal, which has had inserted into its germline genetic material that encodes for at least part of an immunoglobulin of foreign origin, or that can rearrange to encode a repertoire of immunoglobulins.
• the invention also includes within its scope an immunoglobulin produced from a transgenic animal in accordance with the invention or produced by the method of the invention.
• lines of transgenic mice were established, carrying a DNA segment introduced into their germline that contains germline-configuration immunoglobulin VH genes, some of the D segments, and all the JH and Cmu gene segments.
• VH genes, all the JH segments and the exons encoding the secreted heavy-chain constant region of IgM antibody were of human origin, with the remaining material being of mouse origin.
• the gene segments undergo productive VH-D-JH joining in the lymphoid tissue of the transgenic mice, with resultant synthesis of human/mouse chimaeric IgM antibody in serum.
• hybridomas have been established by fusion between spleen cells from the transgenic mice with the NSO myeloma. Many of the hybrids secerete human chimaeric IgM monoclonal antibodies. These lines of transgenic mice can therefore be used for the production of chimaeric human antisera or monoclonal antibodies.
• mice make a response following immunisation with human antigens, producing chimeric antibodies to introduced antigen, and this approach should therefore also prove useful for the production of a repertoire of conventional human or chimaeric human antibodies directed against human as well as heterologous antigens, as the transgenic mice will not be tolerant to human antigenic determinants.
• transgenic mice carrying exclusively human VH, D, JH and C mu sequences were produced by injecting into fertilised mouse eggs cosmids containing human VH genes, D segments, J segments and the C mu constant region. Resulting mice produced between 10 and 100 ug/ml antibody containing human mu chains in their serum, with mouse IgM being present at about 200 ug/ml.
• Figure 1 illustrates the structure of plasmid DNA
• Figure 2 is a Southern blot analysis of DNA from tissues and from hybridomas derived from transgenic mice with th DNA of Figure 1 incorporated into the germline;
• Figure 3 is a Northern blot analysis of cytoplasmic RNA from hybridomas from the transgenic mice
• Figure 4 is an analysis of immunoglobulin secreted by tw of the hydridomas established from the transgenic mice;
• Figure 5 illustrates the structure of IgA lambda plasmid DNA;
• Figure 6 is a series of FACS histograms showing fluorescence intensity of a fixed number of cells plotted against cell number
• Figure 7 is a series of FACS profiles showing fluorescence intensity of a fixed number of cells plotted against scatter, with each dot representing a cell;
• Figure 8 is a further series of FACS histograms similar to Figure 6.
• Plasmid DNA with the structure shown in Figure 1 was injected into mouse eggs.
• human sequences are represented by filled bars; mouse sequences by unfilled bars; vector by cross-hatched bars, and D elements by reverse hatched bars.
• Restriction endonuclease cleavage sites are abbreviated as follows: Bg, Bglll; P, Pvul; R, EcoRI; K, Kpnl; B, BamHI ; X, Xbal; H, Hindlll.
• the provenance of the constituent DNA segments is as follows:
• the Vector The entire "mini-IgH locus" was cloned between the EcoRI and Bglll site of a ⁇ UC12 derivative that contains Bglll linkers cloned into a filled-in Narl site .
• the VH genes There are two VH genes in the mini-locus.
• the VH26 is of human origin and was obtained as a Bglll- EcoRI 0 * 85 Kb fragment from phage lambda VH26 [Matthyssens & Rabbitts (1980) PNAS 11_, 6561-6565].
• the VH-186.2 is a germline VH gene from C57BL/6 mice and was obtained as 2.5 Kb Sacl-Kpnl fragment [Bothwell, Paskind, Reth, Imanishi- Kari, Rajewsky & Baltimore (1981) Cell 2 ⁇ _, 625-637].
• the D segments the BALB/c mouse D-Q52 element was obtained as a 221 nt Xhol-Sacl fragment. Following cloning between the Sad and Sail sites of M13tgl31, site directed mutagenesis with either oligonucleotide
• the JH cluster A 3.5 Kb Bglll fragment from human DNA was used that includes the six functional human JH segments, three pseudo JHs as well as the human D-Q52 element [Ravetch et al. (1981) Cell 21_, 583-591].
• the IgH Enhancers Part of the human IgH enhancer is included within the Bglll fragment containing the JH cluster. A full copy of the mouse enhancer is included within the 1 Kb Xbal fragment.
• the Switch region and Cmu region The 7.5 Kb Xbal fragmen of human DNA includes the mu switch region and exons 1 to 4 of the mu heavy-chain constant region. The mu ' membrane exons and the bulk of the intron between the Cmu4 exon an the CmuMl membrane exon are provided by a 2.5 Kb Hindlll- Sphl fragment of the mouse mu CH gene in which the Sphl site was converted to a Bglll site by use of linkers.
• Plasmid DNA was linearised with Bglll, purified after electrophoresis in an agarose gel and injected into the male pronucleus of fertilised eggs of C57BL/6J x CBA/Ca mice as previously described [Reik et al. (1987) Eur. J. Immunol. JL7_, 465-469]. Southern blot analysis of tail DNA revealed that 12 of the 32 mice born carried the mini locus. Most subsequent work was performed on offsprinq of three founder mice - HIg 17, 19 and 29 all of which carry a low number (2-5) of copies of the mini-locus.
• Serum of the founder mice was tested by ELISA for the presence of antibody containing antigenic determinants characteristic of human IgM.
• the uniminimised fcrr ⁇ nsgenic mice proved to contain between 10 and 100 ug/ml of chimaeric human TgM in their serum.
• Immuno luorescence analysis of lymphocytes in peripheral blood also revealed the presence of cells staining with biotinylated spnoies- specific anti-human Ig M antibody and fluorescein- conjugatei streptavidin.
• Hybridomas from transgenic mice Transgenic mice were immunised intraperitoneally with either human red blood cells or sheep red blood cells. Spleens were removed at various times after immunisation, fused with the NSO myeloma and hybrids selected in HAT medium. Many of these hybrids made chimaeric human IgM s revealed by ELISA assay.
• DNA from tissues or hybridomas established from the transgenic mice was digested with EcoRI and hybridized with a human IgH enhancer probe (Ball-Bglll fragment) that hybridizes to the region between the human J6 element and the mouse IgH enhancer in the mini-locus.
• the results of Southern blot analysis of the DNA are shown in Figure 2. The sizes in Kb of marker fragments are given in the Figure.
• Cytoplasmic RNA (5 ug) from the NSO fusion partner or from hybridomas from the transgenic mice was probed with human Cmu, human VH26 or mouse VH186 probes
• the results of Northern blot analysis of the cytoplasmic RNA are shown in Figure 3, which reveals that the hybridomas contained mRMA that hybridized with probes for human mu as well as for either or both of the VH26 or VH186 V genes.
• both the human VH26 and mouse VH186 are able to rearrange and thus create a cell-line that secretes a chimaeric human IgM antibody.
• Protein production by cloned hybridoma cell-lines was analysed by use of biosynthetic labelling with L-[ 35S] methionine and subsequent purification with anti-human mu antiserum.
• cells were incubated overnight in medium containing L-[ 35S] methionine and IgM antibody purified from the culture supernatant by immunoprecipitation and an anti-human mu antiserum.
• the purification from the supernatants of the transgenic hybridomas 35.5 and 24a was performed in the presence of large excess (50ug) of non-radioactive, purified mouse monoclonal IgM antibody (Bl-8) as indicated by "+" in Figure 4.
• Transgenic animals can be created that produce specific antibodies in both their body fluids and extern ** .! st ⁇ rretions.
• this example concerns transgenic mice that carry integrated into their germline the genes encoding heavy and . light chains of an an igen-specific chimaeric human IgA2 antibody.
• Nine transgenic mouse lines were established that carried germline integrations of the DNA illustrated in Figure 5.
• the thick filled lines depict mouse Ig DNA, the hatched lines human DNA, open boxes the mouse IgH and SV 40 enhancers, and thin filled lines the pSV2gpt vector. Restriction site abreviations are as in Figure 1.
• the plasmid is a derivative of pSV-VNPH alpha 2 described previously [Bruggemann et al, J. Exp. Med (1987) 166, 1351-1361] and contains a 7.4 kb EcoRI fragment including the rearranged lambda 1 gene of the mouse HOPC2020 plasmacytoma [Bernard et al (1978), Cell 5_, 1133-1140]. Plasmid DNA was linearised at the Pvul site in the vector and transgenic mice derived as previously described [Reik et al, Eur. F. Immunol (1987) 11_, 465-469].
• the transgenic IgA 2 lambda antibody has specificity for the hapten 4-hydroxy-3-nitrophenacetyl (NP) .
• Expression of the transgenic antibody was measured by ELISA assay using NP-bovine serum albumin coupled to the plastic plate and developing with a biotinylated anti-human alpha antiserum.
• Total Ig was measured using anti-mouse Ig coated plastic and developing with biotinylated anti- mouse kappa antiserum.
• the concentration of chimaeric anti-NP IgA2 was determined in the colostrum, serum and milk from seven transgenic mice and one control mouse, and the resuts are given in Table 1. Colostrum was taken from the mother following hormonal injection within 24 hours of giving birth and milk was taken from the mother when the litter was 13-15 days old; serum was obtained at the same time as milk.
• transgenic animals can be used for specific antibody production thus allowing lar scale production from milk, colostrum, sera, saliva etc as well as allowing the breeding of animals that yield a milk that is dosed with specific beneficial antibodies. It is also clear that the concentration of transgenic antibody is higher in colostrum than in milk. Moreover, the presence of the transgene does not affect the ability of the animal to make a large amount of endogenous antibody. The animals show no signs of being significantly immunodeficient or unhealthy.
• antigen-specific hybridomas wen * ? produced using human mu chains from transgenic mice.
• transgenic mice described in Example 1 can be used to produce antigen-specific antibodies in which the heavy-chain contribution to the antigen- combining site is .
• the transgenic mice were immunised with ⁇ 10 sheep red cells (SRC). Spleen cells were fused 6 days later with the NSO plasmacytoma (Kbhler and Milstein, Nature, 256, 495-497, 1975). Cells were plated out in 96- well costar plates such that the expected seeding frequency was 1 hybridoma per well. Human mu positive hybrids were detected in an. E ISA using biotinylated anti- human IgM. Antigen-specific hybrids have been identified in haemagglutination using sheep red cells. Wells were chosen that contained antibodies specific for sheep red cells and that contained human mu but neither mouse mu nor mouse gamma heavy chains as determined by LISA.
• FACS fluorescence-activated cell sorter
• Figures 6A, 7A, 8A are results for negative controls using sheep red cells alone, sheep red cells incubated with antibody or sheep red cells incubated with fluorescinated (FITC) second antibody (either anti- human mu anti-mouse mu, anti-mouse kappa) .
• Figures 6B, 7B, 3B are results using sheep red cells incubated with hybrid culture supernatant and fluoresceinated (FITC) anti-human mu.
• Figures 6C, 7C, 8C are results using sheep red cells incubated with culture supernatant from the transgenic hybrids and fluoresceinated (FITC) anti-mouse mu.
• Figure 6D is results using sheep red cells incubated with hybrid culture supernatant and fluoresceinated (FITC) anti-mouse kappa.
• a shift of the profiles to the right denotes a positive stain that can only been seen for antibodies containing human mu heavy chains and mouse kappa light chains but not for antibodies containing mouse mu heavy chains or mouse gamma heavy chains (not shown) .

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Zoology (AREA)
• General Health & Medical Sciences (AREA)
• Biotechnology (AREA)
• Wood Science & Technology (AREA)
• Molecular Biology (AREA)
• General Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Environmental Sciences (AREA)
• Biomedical Technology (AREA)
• Veterinary Medicine (AREA)
• Biophysics (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• Medicinal Chemistry (AREA)
• Plant Pathology (AREA)
• Physics & Mathematics (AREA)
• Animal Behavior & Ethology (AREA)
• Animal Husbandry (AREA)
• Biodiversity & Conservation Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10645060

Family Applications (1)

Country Status (9)

Cited By (286)

Families Citing this family (2365)